Burden and trends of breast cancer worldwide: Opportunities for prevention?

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Key insights from lung cancer research at ASCO 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

ASCO 2025: Importance of early testing in metastatic prostate cancer

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

New MOAs in prostate cancer treatment - what’s next?

Olaparib boosts chemotherapy’s impact on BRCA-mutated breast cancer